Altravax, Inc.
Records under this name other than patents Altravax, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 6 of 6 · Back to Altravax, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,476,390 | Flavivirus antigens Lapsed on the fee record Ended Jan 13, 2021 · From the USPTO record | Lapsed on the fee record | Ended Jan 13, 2021 | From the USPTO record |
| US 9,353,158 | Hepatitis B virus vaccines Lapsed on the fee record Ended May 31, 2020 · From the USPTO record | Lapsed on the fee record | Ended May 31, 2020 | From the USPTO record |
| US 8,168,772 | Nucleic acids encoding novel chimeric C15/prM/E dengue virus immunogens prepared by DNA shuffling Lapsed on the fee record Ended May 1, 2020 · From the USPTO record | Lapsed on the fee record | Ended May 1, 2020 | From the USPTO record |
| US 8,158,131 | Recombinant dengue virus antigens comprising the C15 signal peptide, full-length PRM protein, and full-length E protein Lapsed on the fee record Ended Apr 17, 2020 · From the USPTO record | Lapsed on the fee record | Ended Apr 17, 2020 | From the USPTO record |
| US 9,186,397 | Recombinant dengue virus antigen comprising the capsid protein leader sequence, full-length prM protein, and full-length E protein Lapsed on the fee record Ended Nov 17, 2019 · From the USPTO record | Lapsed on the fee record | Ended Nov 17, 2019 | From the USPTO record |
| US 8,715,694 | Recombinant dengue virus antigen comprising the capsid protein leader sequence, full-length prM protein, and full-length E protein Lapsed on the fee record Ended May 6, 2018 · From the USPTO record | Lapsed on the fee record | Ended May 6, 2018 | From the USPTO record |